Dr. Gerber has over 25 years of R&D experience in oncology drug development, including antibody-drug conjugates (ADCs), T-cell engagers (TCEs, “bispecifics”) and adoptive T-cell therapies (TCR-T and CAR-T cells). Starting at Genentech (11 years), Seattle Genetics (3 years) and Pfizer (8 years), he continued serving various executive roles in different companies (e.g., Maverick Therapeutics, 3T Biosciences, Codeable Therapeutics).

During his career, Dr. Gerber built highly successful drug development teams in pharma, biotech and startup companies and oversaw preclinical development programs for targeted therapeutics in oncology (including target ID, platform- and preclinical program development). He served on boards and raised money for seed and series A financing for multiple biotech startups. Beyond this background, he served as consultant to various VCs evaluating diverse therapeutic modalities.

Dr. Gerber is an internationally recognized leader in Oncology R&D, with a strong track record of accomplishments in the field of targeted therapeutics. His work led to over 10 IND filings for ADCs and TCEs, of which 5 have advanced to phase 2. His teams also contributed to 3 BLAs, including Avastin and 2 ADCs (Mylotarg, Besponsa). He is an author on over 100 peer-reviewed publications in high impact journals and a co-inventor on over 100 issued patents.

Hans-Peter Gerber received an MS in Biochemistry and a PhD in Molecular Biology from the University of Zurich, Switzerland.

Currently, he serves as CSO of Codeable Therapeutics, an ADC startup company focusing on the development of next generation ADCs that induce immunogenic cell death.

Patrik Forrer, CEO, commented: “It is with great enthusiasm that we welcome Hans-Peter to Athebio! With his broad and deep scientific and entrepreneurial background and his extensive experience in the development of targeted therapeutics, he will bring valuable scientific and drug development know-how to Athebio. As we progress towards establishing Athebody® DARPins as “plug & play” building blocks for innovative drugs and move forward with our partnerships, Hans-Peter will play an instrumental role in shaping the future for Athebio and our partners.”

Dr. Gerber added: “I am very excited to be joining Athebio at what is clearly an important stage for the company. Athebio’s proprietary Athebody® DARPin platform has clear potential to support drug developers in creating next generation industry-leading therapeutics. I look forward to joining the strong team at Athebio to help shape the scientific strategy for bringing this promising technology to innovation leaders worldwide.”

For additional information, please contact us:
Phone: +41 44 508 08 28

Email: contact@athebio.com